The Regulatory Governance Gap In Clinical Trial AI

By John Paul (JP) Lee, COO, AG Mednet

The FDA and EMA are clear that AI-generated decisions in clinical trials must meet the same standards of accountability, traceability, and reproducibility as human ones. That means regulators are no longer evaluating AI systems solely on performance. They are evaluating the operational framework surrounding it. Validation records, audit trails, governance controls, reproducibility evidence, and documented decision pathways are quickly becoming mandatory requirements for any AI system influencing regulated trial activity.

This is changing how many organizations are approaching AI adoption. Most clinical AI implementations were designed to improve speed and automate workflows, but few were designed to create the continuous documentation trail regulators expect during an inspection or submission review. The problem, then, is not the model itself. It is the infrastructure surrounding the model. 

This is exactly the challenge Judi was designed to solve. At AG Mednet, governance, workflow orchestration, accountability, and multi-stakeholder oversight were built into the architecture from the beginning because regulated clinical operations have always required them. As AI adoption accelerates, those capabilities move from operational advantages to regulatory necessities.